PE20080259A1 - Compuestos y metodos para modular fxr - Google Patents

Compuestos y metodos para modular fxr

Info

Publication number
PE20080259A1
PE20080259A1 PE2007000629A PE2007000629A PE20080259A1 PE 20080259 A1 PE20080259 A1 PE 20080259A1 PE 2007000629 A PE2007000629 A PE 2007000629A PE 2007000629 A PE2007000629 A PE 2007000629A PE 20080259 A1 PE20080259 A1 PE 20080259A1
Authority
PE
Peru
Prior art keywords
alkyl
methyl
haloalkyl
compounds
ilmetoxy
Prior art date
Application number
PE2007000629A
Other languages
English (en)
Inventor
Michael Gregory Bell
Robert Anthony Doti
Michael James Genin
Peter Ambrose Lander
Tianwei Ma
Nathan Bryan Mantlo
Jason Matthew Ochoada
Lindsay Scott Stelzer
Ryan Edward Stites
Alan M Warshawsky
Matthew Scott Dowling
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20080259A1 publication Critical patent/PE20080259A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I DONDE p 0-1; X1 y X2 SON C, N CON LA CONDICION DE QUE AMBOS X1 y X2 NO SON N; R1 y R2 SON H, ALQUILO C1-C3, HALOALQUILO C1-C3, ENTRE OTROS; R4b ES H, ALQUILO C1-C3, HALOALQUILO C1-C3, ENTRE OTROS; R5 y R5a SON CADA UNO H, ALQUILO C1-C3; R6 ES H, ALQUILO C1-C3, HALOALQUILO C1-C3, ENTRE OTROS; L1 ES ENLACE, ETINILO, ALQUILO C1-C3, ENTRE OTROS; Ar1 ES INDOLILO, BENZOTIENILO, NAFTILO, ENTRE OTROS; R7 ES -COOH, -ALQUILO C1-C3COOH, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ACIDO 4-[({4-[3-(2,6-DICLOROFENIL)-5-TRIFLUOROMETIL-3H-[1,2,3]TRIAZOL-4-ILMETOXI]-2-METILOFENIL}-METILAMINO)-METILO]-2-METIL-BENZOICO; ACIDO 3-[({4-[3-(2,6-DICLORO-FENIL)-5-ISOPROPIL-3H-[1,2,3]TRIAZOL-4-ILMETOXI]-2-METIL-FENIL}-METIL-AMINO)-METILO]-BENZOICO; ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. LOS COMPUESTOS DESCRITOS SON AGONISTAS SELECTIVOS PARA EL FXR (RECEPTOR FARMESOIDE X) UTILES EN EL TRATAMIENTO DE DISLIPIDEMIA, ATEROESCLEROSIS, DIABETES Y ENFERMEDADES RELACIONADAS
PE2007000629A 2006-05-24 2007-05-22 Compuestos y metodos para modular fxr PE20080259A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80810406P 2006-05-24 2006-05-24
US87000106P 2006-12-14 2006-12-14

Publications (1)

Publication Number Publication Date
PE20080259A1 true PE20080259A1 (es) 2008-04-10

Family

ID=38626336

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000629A PE20080259A1 (es) 2006-05-24 2007-05-22 Compuestos y metodos para modular fxr

Country Status (16)

Country Link
US (1) US8106077B2 (es)
EP (1) EP2029558B1 (es)
JP (1) JP5225984B2 (es)
AR (1) AR061101A1 (es)
AT (1) ATE460403T1 (es)
AU (1) AU2007267692B2 (es)
BR (1) BRPI0711875A2 (es)
CA (1) CA2651373A1 (es)
CL (1) CL2007001451A1 (es)
DE (1) DE602007005256D1 (es)
EA (1) EA014720B1 (es)
ES (1) ES2340221T3 (es)
MX (1) MX2008014959A (es)
PE (1) PE20080259A1 (es)
TW (1) TW200812982A (es)
WO (1) WO2007140174A2 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1894924A1 (en) * 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP1894928A1 (en) * 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
TW200906823A (en) * 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8217064B2 (en) 2007-12-20 2012-07-10 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
WO2009102761A1 (en) 2008-02-12 2009-08-20 Bristol-Myers Squibb Company 1,2,3-triazoles as 11-beta hydroxysteroid dehydrogenase type i inhibitors
EP2128158A1 (en) 2008-05-26 2009-12-02 Phenex Pharmaceuticals AG Heterocyclic cyclopropyl-substituted FXR binding compounds
WO2010034649A1 (en) * 2008-09-25 2010-04-01 F. Hoffmann-La Roche Ag 2,3-substituted indazole or 4,5,6,7-tetrahydro-indazoles as fxr modulators against dyslipidemia and related diseases
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8252826B2 (en) 2010-03-24 2012-08-28 Hoffmann-La Roche Inc. Cyclopentyl- and cycloheptylpyrazoles
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2012044531A1 (en) 2010-09-28 2012-04-05 Bristol-Myers Squibb Company Novel piperazine analogs with substituted heteroaryl groups as broad-spectrum influenza antivirals
US8742097B2 (en) * 2010-11-09 2014-06-03 Hoffmann-La Roche Inc. Triazole compounds I
ES2536667T3 (es) * 2010-11-09 2015-05-27 F. Hoffmann-La Roche Ag Derivados de triazol como ligandos de receptores Gaba
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
IL253437A0 (en) * 2011-07-13 2017-09-28 Gilead Sciences Inc New compounds modulate fxr (nr1h4) activity and bind
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
IN2014DN11027A (es) * 2012-06-26 2015-09-25 Aniona Aps
RS61540B1 (sr) 2013-09-11 2021-04-29 Inst Nat Sante Rech Med Postupci i farmaceutske kompozicije za tretiranje infekcije hepatitis b virusa
JP2017505770A (ja) 2014-01-24 2017-02-23 シンアフィックス ビー．ブイ． （ヘテロ）アリール１，３−双極子化合物と（ヘテロ）シクロアルキンとの環化付加のためのプロセス
EP3006939A1 (en) 2014-10-06 2016-04-13 Gilead Sciences, Inc. Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
MA41094A (fr) * 2014-12-02 2017-10-10 Lilly Co Eli Procédés de traitement de troubles rénaux
EP3034501A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
US11311557B2 (en) 2015-02-06 2022-04-26 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions for combination therapy
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
KR20170132879A (ko) 2015-04-07 2017-12-04 인터셉트 파마슈티컬즈, 인크. 조합 요법을 위한 약제학적 조성물
EP3730487B1 (en) 2016-06-13 2022-04-27 Gilead Sciences, Inc. Azetidine derivatives as fxr (nr1h4) modulators
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
SG11201906987RA (en) 2017-02-21 2019-09-27 Genfit Combination of a ppar agonist with a fxr agonist
PT3600309T (pt) 2017-03-28 2022-10-03 Gilead Sciences Inc Combinações terapêuticas para o tratamento de doenças hepáticas
CN110944635A (zh) 2017-03-30 2020-03-31 国家医疗保健研究所 用于减少附加体病毒的持久性和表达的方法和药物组合物
KR102168543B1 (ko) 2017-04-12 2020-10-21 일동제약(주) 핵 수용체의 효능제인 아이속사졸 유도체 및 이의 용도
EP3704107B1 (en) 2017-11-01 2023-04-12 Bristol-Myers Squibb Company Multicyclic compounds as farnesoid x receptor modulators
EA202091084A1 (ru) 2017-11-01 2020-08-13 Бристол-Маерс Сквибб Компани Алкеновые спироциклические соединения как модуляторы фарнезоидных x-рецепторов
CN111511731B (zh) 2017-11-01 2023-05-23 百时美施贵宝公司 作为法尼醇x受体调节剂的烯烃化合物
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
IT201800007265A1 (it) * 2018-07-17 2020-01-17 Isossazoli come agonisti del recettore fxr
BR102019014802A2 (pt) 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
HU231223B1 (hu) 2018-09-28 2022-01-28 Richter Gedeon Nyrt. GABAA A5 receptor modulátor hatású biciklusos vegyületek
SI3911647T1 (sl) 2019-01-15 2024-04-30 Gilead Sciences, Inc. Izoksazolna spojina kot agonist FXR in farmacevtski sestavki, ki jo obsegajo
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
CN114144185A (zh) 2019-05-30 2022-03-04 英特塞普特医药品公司 用于治疗胆汁淤积性肝病的包含fxr激动剂和贝特类的药物组合物
KR20220035365A (ko) 2019-07-18 2022-03-22 엔요 파마 인터페론의 부작용을 감소시키는 방법
CN110878052B (zh) * 2019-12-11 2021-05-07 山东大学 一种含有fxr激动剂的化合物及其制备方法和应用
WO2021144330A1 (en) 2020-01-15 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
WO2021191837A1 (en) 2020-03-26 2021-09-30 Richter Gedeon Nyrt. 1,3-dihydro-2h-pyrrolo[3,4-c]pyridine derivatives as gabaa α5 receptor modulators
JP2024502673A (ja) 2021-01-14 2024-01-22 ウエヌイグレックオ・ファーマ Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果
JP2024517181A (ja) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ 組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07138258A (ja) * 1993-11-16 1995-05-30 Taiho Yakuhin Kogyo Kk チアゾリジンジオン誘導体又はその塩
DE60131967D1 (de) 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
US7319109B2 (en) * 2002-11-22 2008-01-15 Smith Kline Beecham Corporation Farnesoid X receptor agonists
JP2007515484A (ja) * 2003-12-22 2007-06-14 イーライ リリー アンド カンパニー トリアゾール、オキサジアゾール、及びチアジアゾール誘導体のｐｐａｒ修飾物質

Also Published As

Publication number Publication date
US20090093524A1 (en) 2009-04-09
TW200812982A (en) 2008-03-16
JP2009538333A (ja) 2009-11-05
MX2008014959A (es) 2008-12-09
JP5225984B2 (ja) 2013-07-03
EP2029558B1 (en) 2010-03-10
AU2007267692B2 (en) 2012-06-14
CA2651373A1 (en) 2007-12-06
AR061101A1 (es) 2008-08-06
ATE460403T1 (de) 2010-03-15
DE602007005256D1 (de) 2010-04-22
EA014720B1 (ru) 2011-02-28
ES2340221T3 (es) 2010-05-31
US8106077B2 (en) 2012-01-31
WO2007140174A2 (en) 2007-12-06
BRPI0711875A2 (pt) 2012-01-10
WO2007140174A3 (en) 2008-03-20
EA200870569A1 (ru) 2009-06-30
AU2007267692A1 (en) 2007-12-06
CL2007001451A1 (es) 2008-01-11
EP2029558A2 (en) 2009-03-04

Similar Documents

Publication Publication Date Title
PE20080259A1 (es) Compuestos y metodos para modular fxr
PE20050018A1 (es) Compuesto pentaciclico heteroaromatico como inhibidor de la proteina tirosina fosfatasa 1b (ptb1b)
PE20110905A1 (es) Arilpirrolidinas pesticidas
PE20051173A1 (es) Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3
PE20110672A1 (es) 4-fenil-1-h-pirazoles insecticidas
PE20080362A1 (es) Derivados de ciclohexilpirazol-lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
PE20110341A1 (es) COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA
PE20050444A1 (es) Compuestos de piridina como inhibidores de la peptidasa
PE20090641A1 (es) Amidas heterociclicas
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20090992A1 (es) Derivados de fenil-amino-pirimidina como agentes inhibidores de cinasa
PE20081475A1 (es) Arilamidas sustituidas por tiazol u oxazol
PE20010987A1 (es) Inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias
PE20051054A1 (es) Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento
PE20081545A1 (es) Derivados de sulfonamida como inhibidores de acido graso sintasas
PE20051147A1 (es) Compuestos de heteroaril y fenilsulfamoilo sustituidos
PE20060427A1 (es) Derivados de pirazol como inhibidores de la union del glucagon y composiciones
PE20091425A1 (es) Derivados de aminotiazol
AR094588A2 (es) Proceso de obtención de un compuesto derivado de benzimidazol y composición farmacéutica
PE20081404A1 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona y procesos para su preparacion
CO5550431A2 (es) Cristales que incluyen una sal de acido malico de n-[2 (dietilamino)etil]-5-[(5-fluoro-2oxo-3h-indol-3-ilideno) metil]-2,4-dimetil-1h-pirrol-3-carboxamida, proceso para su preparacion y composiciones de esta
PE20030547A1 (es) Derivados de imidazol para el tratamiento de la obesidad
PE20141943A1 (es) Antagonistas de trpv4
PE20060240A1 (es) Derivados de pirimidina para tratar el crecimiento celular anomalo
AR071609A1 (es) Inhibidores ciclicos de 11(beta) -hidroxiesteroide deshidrogenasa 1

Legal Events

Date Code Title Description
FD Application declared void or lapsed